Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1341-1360 of 2,251 trials

Advanced Gastric Cancer: New Drug Combinations

We are studying whether a new combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is more effective than standard treatment for patients with advanced gastric or esophageal cancer. The goal is to improve survival and quality of life for those with HER2 negative cancer.

HER2 Negative Gastric CancerEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

NY-ESO-1 T-Cells for Synovial Sarcoma and Liposarcoma

We are studying genetically engineered T cells in patients with synovial sarcoma and myxoid/round cell liposarcoma. The goal is to see if this treatment is effective and safe for those with specific tumor markers.

Myxoid and Round Cell LiposarcomaSynovial SarcomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Long-Term Follow-Up of Adoptive Cell Therapies

We are monitoring individuals who received genetically modified cell treatments to check for any delayed side effects and how long these cells remain in the body. This study aims to ensure safety and understand the treatment's long-term effects.

Myxoid LiposarcomaMultiple MyelomaSynovial Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

HPV Vaccination After Cervical Lesion Treatment

We are studying whether a secondary HPV vaccination helps women over 45 who have been treated for high-grade cervical lesions achieve HPV-negative status and reduce the risk of recurrence or cancer.

High-Grade Cervical Intraepithelial Lesions>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Metastatic Non-Small Cell Lung Cancer: Ivonescimab vs Pembrolizumab

We are studying whether ivonescimab combined with chemotherapy helps patients with metastatic non-small cell lung cancer live longer and manage their disease better than pembrolizumab with chemotherapy.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Cryptogenic Stroke: STOP Trial on Blood Thinners

We are studying whether stopping blood thinners is as safe as continuing them for young people after a stroke with no known cause. This research may help understand the best approach to prevent future heart problems.

Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

MEN1703 for Aggressive B-cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of MEN1703 alone and with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. This research aims to find better treatment options for this challenging cancer.

Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vaginal Progesterone for Fertility: Standard vs. New Formulation

We are comparing two formulations of vaginal progesterone to see which one better supports pregnancy in women undergoing fertility treatments. This study aims to improve pregnancy rates and assess safety for participants.

Infertility>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Oxygen Management During Anesthesia: The LOWOX Trial

We are studying whether a tailored approach to oxygen levels during anesthesia improves recovery and oxygen levels after surgery compared to standard fixed oxygen use. This trial involves patients undergoing various surgical procedures.

Surgery under General Anesthesia3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Head and Neck Cancer: New Drug Combinations

We are studying a new combination of drugs for patients with recurrent or metastatic head and neck cancer. The goal is to see if this combination works better than the current treatment options.

Recurrent Head and Neck Squamous Cell CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

HER2-Positive Gastric Cancer: Trastuzumab Deruxtecan Study

We are testing a new treatment combining Trastuzumab Deruxtecan with chemotherapy for patients with advanced HER2-positive gastric or GEJ cancer. The goal is to see if this combination works better than the current standard treatment.

Metastatic Gastric Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Venous Ulcers: Stem Cell Treatment Study

We are testing a new treatment using adipose tissue stem cells for people with venous ulcers in their lower limbs. The study aims to see if this treatment helps wounds heal faster and improves quality of life.

Venous Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyInternal Medicine

Botulinum Toxin for Spastic Equinovarus in Stroke Patients

We are exploring how a treatment with botulinum toxin type A affects muscle and nerve properties in people who have had their first stroke. This study aims to gather insights that could improve future treatments for spastic equinovarus.

Spastic Equinovarus in Stroke Patients3-6 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Surgery Fluid Study: Albumin vs. Ringer's Solution

We are comparing two fluids to see which one better supports blood volume and circulation during laparoscopic surgery. This research may help improve patient care in surgical settings.

Fluid Therapy in Laparoscopic Surgery>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOtolaryngology

Weight Loss in HIV: Semaglutide Study

We are investigating whether the medication semaglutide can help people living with HIV and obesity lose more weight when combined with diet and exercise. The study also looks at its effects on inflammation and overall health.

HIV and Obesity6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyInfectious Diseases